Cencora COR is slated to report first-quarter ... respectively. However, the PharmaLex business growth is not keeping up with original expectations as the outsourced pharma services market faces ...

Cencora also acquired PharmaLex, which provides business and consulting support to biopharma firms. While the firm is still working on fully integrating this business, we think it could be another ...

Cencora, Inc. COR is well-poised for growth ... A $418-million goodwill impairment on PharmaLex reflects underperformance in outsourced pharma services due to market pressures.

Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $300 million, “primarily for debt paydown and general corporate purposes,” the company said ...

Over the past year, many Cencora, Inc. ( NYSE:COR ) insiders sold a significant stake in the company which may have... CONSHOHOCKEN, Pa., February 07, 2025--Cencora, Inc. (NYSE: COR) today ...

Cencora (NYSE:COR) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding ...

Cencora has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance’s sale ...

Walgreens is offloading more shares in drug distributor Cencora as the struggling pharmacy chain looks to generate cash. The latest sale netted about $300 million for Walgreens, and shrinks the ...

Cencora (COR) has significantly expanded the number and type of medications available in its sure supply program, a drug shortage mitigation initiative designed to provide health systems with ...

Hello and welcome everyone to the Cencora Q1 fiscal year 2025 earnings call. My name is Becky and I’ll be your Operator today. During the presentation, you can register a question by pressing ...